title: CNS complications of radiotherapy and chemotherapy.
abstract: Treatment-induced CNS toxicity remains a major cause of morbidity in patients with cancer. Advances in the design of safe radiation procedures have been counterbalanced by widespread use of combined radiotherapy and chemotherapy, development of radiosurgery, and the increasing number of long-term survivors. Although classic radionecrosis and chemonecrosis have become less common, subtle changes such as progressive cognitive dysfunction are increasingly reported after radiotherapy (radiation-induced leukoencephalopathy) or chemotherapy (given alone or in combination). We review the most important and controversial complications of radiotherapy, chemotherapy, and combined treatments in the CNS, and discuss new diagnostic tools, practical management, prevention, and pathophysiological data that will affect future management of patients with cancer.
authors.affiliation: INSERM, U975, Paris, France.
authors.forename: Carole
authors.initials: C
authors.lastname: Soussain
authors.forename: Damien
authors.initials: D
authors.lastname: Ricard
authors.forename: John R
authors.initials: JR
authors.lastname: Fike
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Mazeron
authors.forename: Dimitri
authors.initials: D
authors.lastname: Psimaras
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
mesh_terms: D000359:Aftercare; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015984:Causality; D002493:Central Nervous System Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D003072:Cognition Disorders / Q000209:etiology; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006801:Humans; D008279:Magnetic Resonance Imaging; D009017:Morbidity; D009369:Neoplasms / Q000150:complications / Q000628:therapy; D011878:Radiotherapy / Q000009:adverse effects*; D012449:Safety; D017741:Survivors / Q000706:statistics & numerical data
chemical_list: D000970:Antineoplastic Agents